Verzenio, Verzenios(abemaciclib)
Verzenio, Verzenios (abemaciclib) is a small molecule pharmaceutical. Abemaciclib was first approved as Verzenio on 2017-09-28. It has been approved in Europe to treat breast neoplasms. It is known to target cyclin-dependent kinase 6 and cyclin-dependent kinase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Verzenio
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| verzenio | New Drug Application | 2025-02-27 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ABEMACICLIB, VERZENIO, ELI LILLY AND CO | |||
| 2024-10-12 | I-877, NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Abemaciclib, Verzenio, Eli Lilly And Co | |||
| 7855211 | 2029-12-15 | DS, DP | U-1981, U-2132, U-2135, U-2251, U-3241, U-3242, U-3243, U-3265, U-3546 |
HCPCS
No data
Clinical
Clinical Trials
241 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 13 | 18 | 8 | 4 | 4 | 45 |
| Neoplasms | D009369 | — | C80 | 13 | 11 | 3 | 1 | — | 25 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 4 | 3 | 1 | — | 13 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 2 | — | 1 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 7 | 4 | 1 | — | — | 10 |
| Prostatic neoplasms | D011471 | — | C61 | 3 | 7 | 2 | — | — | 9 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 4 | 1 | — | — | 6 |
| Male breast neoplasms | D018567 | — | — | 1 | 1 | 1 | — | — | 3 |
| Liposarcoma | D008080 | — | — | — | 1 | 1 | — | — | 2 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | 1 | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 6 | 7 | — | — | — | 10 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 7 | — | — | — | 8 |
| Adenocarcinoma | D000230 | — | — | 3 | 6 | — | — | — | 7 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 5 | — | — | — | 5 |
| Sarcoma | D012509 | — | — | 2 | 3 | — | — | — | 5 |
| Glioma | D005910 | EFO_0000520 | — | 3 | 2 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 4 | — | — | — | 4 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 3 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 3 | 1 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 3 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Unilateral breast neoplasms | D000069584 | — | — | 1 | — | — | — | — | 1 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | — | — | — | 1 |
| Microsatellite instability | D053842 | — | — | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Second primary neoplasms | D016609 | — | — | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Polycythemia vera | D011087 | — | D45 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abemaciclib |
| INN | abemaciclib |
| Description | Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
|
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1231929-97-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301610 |
| ChEBI ID | — |
| PubChem CID | 46220502 |
| DrugBank | DB12001 |
| UNII ID | 60UAB198HK (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Verzenio – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,065 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,087 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use